Corcept settles patent dispute with Hikma over Cushing’s syndrome drug

Dec. 08, 2022 12:39 PM ETCorcept Therapeutics Incorporated (CORT), HKMPFTEVABy: Dulan Lokuwithana, SA News Editor

Solution Concept with Handshake on Chalkboard Background

phototechno/iStock via Getty Images

  • Corcept Therapeutics (NASDAQ:CORT) announced an agreement with Hikma Pharmaceuticals (OTCPK:HKMPF) USA on Thursday to resolve the ongoing patent lawsuit related to Korlym, an oral therapy indicated for patients with Cushing’s syndrome.
  • The litigation was filed

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.